The estimated Net Worth of Jan M Lundberg is at least $12.2 Million dollars as of 1 February 2018. Jan Lundberg owns over 36,252 units of Ardelyx Inc stock worth over $1,277,198 and over the last 15 years he sold ARDX stock worth over $10,827,221. In addition, he makes $141,985 as Independent Director at Ardelyx Inc.
Sign up
Jan Lundberg ARDX stock SEC Form 4 insiders trading
Jan has made over 12 trades of the Ardelyx Inc stock since 2011, according to the Form 4 filled with the SEC. Most recently he exercised 36,252 units of ARDX stock worth $216,062 on 1 February 2018.
The largest trade he's ever made was selling 121,711 units of Ardelyx Inc stock on 1 February 2015 worth over $8,614,705. On average, Jan trades about 14,172 units every 88 days since 2010. As of 1 February 2018 he still owns at least 214,295 units of Ardelyx Inc stock.
You can see the complete history of Jan Lundberg stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Jan Lundberg biography
Dr. Jan M. Lundberg Ph.D. serves as Independent Director of the Company. Dr. Lundberg served as the President of Lilly Research Laboratories and Executive Vice President of Science and Technology for Eli Lilly and Company (NYSE: LLY) from January 2010 to March 2018. Prior to joining Lilly he served for ten years as global head of discovery research at AstraZeneca Plc (NYSE: AZN), where he was a member of the senior executive team. Dr. Lundberg also served as a professor at the Karolinska Institute’s department of pharmacology in Sweden, and was a cofounder of biotechnology company, Aerocrine. Dr. Lundberg currently serves on the board of directors of several privately held life sciences companies and non-profit organizations. Dr. Lundberg was instrumental in the establishment of the Innovative Medicines Initiative in Europe and the Accelerating Medicines Partnership with National Institutes of Health. Dr. Lundberg received a B.S.M. in medicine from the University of Gothenberg and a Ph.D. in pharmacology from the Karolinska Institute in Sweden. Lundberg is qualified to serve on our board of directors due to his extensive scientific research background and significant life science industry experience.
What is the salary of Jan Lundberg?
As the Independent Director of Ardelyx Inc, the total compensation of Jan Lundberg at Ardelyx Inc is $141,985. There are 11 executives at Ardelyx Inc getting paid more, with Michael Raab having the highest compensation of $1,728,920.
How old is Jan Lundberg?
Jan Lundberg is 66, he's been the Independent Director of Ardelyx Inc since 2018. There are 1 older and 18 younger executives at Ardelyx Inc. The oldest executive at Ardelyx Inc is Gordon Ringold, 69, who is the Independent Director.
What's Jan Lundberg's mailing address?
Jan's mailing address filed with the SEC is C/O ARDELYX, INC., 400 FIFTH AVENUE, SUITE 210, WALTHAM, MA, 02451.
Insiders trading at Ardelyx Inc
Over the last 10 years, insiders at Ardelyx Inc have traded over $37,312,621 worth of Ardelyx Inc stock and bought 85,247,838 units worth $820,614,871 . The most active insiders traders include Forest Baskett, Scott D Sandell und Anthony A. Jr. Florence. On average, Ardelyx Inc executives and independent directors trade stock every 12 days with the average trade being worth of $1,784,764. The most recent stock trade was executed by Michael Raab on 27 August 2024, trading 7,500 units of ARDX stock currently worth $46,650.
What does Ardelyx Inc do?
ardelyx is focused on enhancing the way people with renal diseases are treated by developing first-in-class medicines. ardelyx's renal pipeline includes the phase 3 development of tenapanor for the treatment of hyperphosphatemia in people with end-stage renal disease who are on dialysis and rdx013, a potassium secretagogue program for the potential treatment of high potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease. in addition, ardelyx has completed phase 3 development of tenapanor for the treatment of irritable bowel syndrome with constipation and anticipates submitting a new drug application to the u.s. food and drug administration for this indication in the second half of 2018. to efficiently bring its treatments to market, ardelyx is pursing strategic collaborations in the u.s. and other countries, including through established agreements with kyowa hakko kirin in japan, fosun pharma in china and knight therapeutics in canada.
What does Ardelyx Inc's logo look like?
Complete history of Jan Lundberg stock trades at Ardelyx Inc und Lilly(Eli) & Co
Ardelyx Inc executives and stock owners
Ardelyx Inc executives and other stock owners filed with the SEC include:
-
Michael Raab,
President, Chief Executive Officer, Director -
Michael G. Raab,
Pres, CEO & Director -
David Rosenbaum,
Chief Development Officer -
Elizabeth Grammer,
Chief Legal and Administrative Officer -
Susan Rodriguez,
Chief Commercial Officer -
Justin A. Renz CPA, MST, M.S.T., MBA,
CFO & Chief Accounting Officer -
Geoffrey Block,
Independent Director -
David Mott,
Independent Chairman of the Board -
Richard Rodgers,
Independent Director -
Gordon Ringold,
Independent Director -
William Bertrand,
Independent Director -
Jan Lundberg,
Independent Director -
Robert Bazemore,
Independent Director -
Onaiza Cadoret-Manier,
Independent Director -
Susan Rodriguez,
Chief Commercial Officer -
Justin Renz,
Chief Accounting and Principal Financial Officer -
Dr. Laura A. Williams M.D., M.P.H.,
Chief Medical Officer -
Dan Pavicich,
Sr. Director of Market Devel. -
David P. Rosenbaum,
Chief Devel. Officer -
Elizabeth A. Grammer,
Chief Legal & Admin. Officer and Sec. -
Karen Harrigan,
Sr. Director Market Devel. -
Robert C. Blanks,
Chief Regulatory Affairs & Quality Assurance Officer -
Sarah O'Brien,
Chief People Officer -
Kimia Keshtbod,
Mang. of Corp. Communications & Investor Relations -
Jeffrey W. Jacobs,
Chief Scientific Officer -
Peter W. Sonsini,
10% owner -
Jon Sakoda,
10% owner -
Patrick J Kerins,
10% owner -
15 Gp, Llc Nea,
10% owner -
Jeremy S Caldwell,
EVP, Chief Scientific Officer -
Mark Kaufmann,
Chief Financial Officer -
Harry R Weller,
10% owner -
Ravi Viswanathan,
10% owner -
Krishna Kittu Kolluri,
10% owner -
Peter J Barris,
10% owner -
Reginald Seeto,
Chief Operating Officer -
Scott D Sandell,
10% owner -
Anthony A. Jr. Florence,
10% owner -
Enterprise Associates 12, L...,
-
Annalisa Jenkins,
Director -
Paul Korner,
EVP, Chief Medical Officer -
Joshua Makower,
10% owner -
Forest Baskett,
10% owner -
M James Barrett,
10% owner -
Eric Duane Foster,
Chief Commercial Officer -
Enterprise Associates 12, L...,
10% owner -
Partners 12, Limited Partne...,
-
Mohamad Makhzoumi,
10% owner -
Muna Bhanji,
Director -
Mike Kelliher,
See Remarks -
Narani Arasaratnam,
VP, Corporate Controller -
Ventures Vii Lpcmea Venture...,
-
Peter G Schultz,
Director -
Ryan D Drant,
10% owner -
George Jue,
VP, Operations & Facilities -
Partners 12, Limited Partne...,
-
Jeffrey W Jacobs,
Chief Scientific Officer -
Robert Ora Felsch,
See Remarks -
Robert Blanks,
See Remarks -
Laura A Williams,
Chief Medical Officer